INOVIO 3rd Quarter 2026 Financial Results Conference Call - INOVIO PHARMACEUTICALS INC

Explicit Guidance:

• Cash Runway: Current liquidity (including $80.5M equity proceeds, $48.4M cash/equivalents as of Q3 2026, and $10.9M warrant exercises) supports operations through the late fourth quarter of 2027, extending past the commercial launch of Viseric.
• Operating Expenses: Projected operational net cash burn of approximately $21 million for the fourth quarter of 2026.
• Revenue Timing: Product sales for Viseric are expected to commence in 2027.

Business-Segment Outlook:

• Viseric (RRP) Commercialization:
  • Market Size: Estimated prevalent population of at least 25,000 adult patients with Recurrent Respiratory Papillomatosis (RRP) in the U.S., with continued new diagnoses.
  • Adoption Goal: Aim to establish Viseric as the preferred first-line treatment for adults with RRP.
  • Launch Timeline: Product expected to be available for order and ship approximately 60 days post-approval; full field deployment planned for the first quarter of 2027.
  • Field Footprint: Deployment of 20 territories with 20-person field team (including key account managers and reimbursement specialists) designed to cover 90% of the RRP patient potential.
  • Reimbursement: Expect policies from insurers covering approximately 80% of U.S. patients to be in place within nine months of approval; planning to apply for a permanent J-code.
  • Manufacturing: Device and plasma manufacturing capacity sufficient to meet anticipated demand through the first year of launch and at least 2027.
• Pipeline Expansion (Viseric):
  • Indications: Plans to expand into pediatric RRP and evaluate continued treatment options for adults.
  • Geographies: Submitting an application for conditional marketing authorization in Europe (EU/UK) before the end of 2026.
  • Commercialization Model: Plan to commercialize Viseric independently in the U.S.; actively seeking partnerships for ex-U.S. territories where FDA approval may not suffice or resources are limited.
• Future Pipeline:
  • Protein Replacement Candidates: Evaluating DPROC candidates for rare diseases including Hemophilia A, Fabry disease, and hypophosphatasia; seeking new partnerships for these early-stage programs.
  • Partnerships: Prioritizing partnerships to advance later-stage clinical candidates and seeking new agreements for next-generation DPROC candidates.

Market and Competitive Outlook:

• Competitive Landscape: Current RRP market is dominated by surgery; immunotherapy has reached only a small fraction of the prevalent patient population, indicating significant unmet demand for non-surgical options.
• Treatment Paradigm Shift: Key opinion leaders and the RRP Foundation have identified immunotherapy as the recommended first-line therapy to reduce permanent vocal cord damage from repeated surgeries.
• Differentiation: Viseric distinguishes itself by eliminating the need for scoping or surgery during the dosing window, a key factor in patient preference and physician adoption.
• Target Audience: Approximately 400 laryngologists treat the majority of patients; 80% of patients receive care in ~100 large Integrated Delivery Networks (IDNs) or academic institutions, with the remaining 20% in community hospitals. The launch strategy targets 100 IDNs and a broader community footprint.

Macro / Industry Outlook:

• Regulatory Environment: Management notes that continued approval of Viseric is contingent on the verification of clinical benefit via a confirmatory study.
• Global Expansion Strategy: Management acknowledges that some regions accepting FDA approval lack the resources to fund commercialization, necessitating a strategic assessment of geographical expansion and distribution partnerships.

Strategic Initiatives:

• Confirmatory Study: Submit a draft protocol for the FDA-required confirmatory study before year-end 2026; target FDA alignment on final protocol by mid-2027. Study aims to enroll at least 50 adult and pediatric patients requiring three or more surgical interventions, evaluating surgical intervention reduction over at least three years post-treatment against an external control.
• Commercial Infrastructure: Deployment of a dedicated "VOSERIC support program" (single point of contact for ordering, benefits verification, co-pay support, and patient assistance) to be active upon product availability.
• Field Deployment: Partnership with "Cineos Health" to rapidly scale field teams; deployment of Medical Science Liaisons (MSLs) to engage Key Opinion Leaders (KOLs).
• Training: Leverage the ease of use (30-minute training) for the Selectra device; training to commence upon product availability.
• Capital Raising: Completed equity offering for $80.5M net proceeds to fund commercial build-out.

Risks and Headwinds to Outlook:

• Regulatory Conditions: Continued approval is dependent on the results of the confirmatory study; failure to verify clinical benefit could jeopardize the product's market status.
• Financial Volatility: Net loss results are subject to significant variability due to non-cash fair value adjustments related to warrant liabilities, which fluctuate with share price and market inputs.
• Execution Risks: Commercial success depends on the rapid adoption of the new therapy by physicians and payers, potential delays in J-code issuance, and successful reimbursement negotiations.
• Market Adoption: While 80% of patients are in IDNs, capturing the 20% in community settings requires effective deployment of the field team; market uptake may be slower than anticipated if payer policies are not implemented within the expected nine-month window.

Management Tone on the Future:

• Confidence Level: High confidence in the platform's validation and the product's commercial potential, citing strong clinical data (50-100% reduction in surgeries in Year 1, durable responses in Years 2-3) and the clear unmet need.
• Strategic Shift: Expresses excitement about the transition to a "commercial stage company" and describes the current phase as a "transformative time" and "pivotal moment."
• Platform Validation: Management views the Viseric approval as proof of concept for the broader DNA medicine platform, expecting it to accelerate interest in other pipeline assets (e.g., DPROC candidates).

Miscellaneous:

• Clinical Data Durability: Long-term data (up to three years) published in Nature Communications and Laryngoscope demonstrate sustained clinical benefit and immune response linkage.
• Safety Profile: Product found well-tolerated with mostly low-grade (Grade 1) adverse events (injection site pain, fatigue); safety data supported by over 1,100 administrations of related HPV programs.
• Device Technology: Utilizes proprietary Selectra device; noted as potentially the "first approved electroporation device in the world," strengthening CMC knowledge for future programs.